Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

被引：0

作者：

Hu, Bei ^{[1
]}

Korsos, Victoria ^{[2
]}

Palomba, M. Lia ^{[2
,3
]}

机构：

[1] Wake Forest Sch Med, Atrium Hlth Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC 28202 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Cellular Therapy Serv, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

chimeric antigen receptor T cell therapy (CAR T cell therapy); diffuse large B cell lymphoma (DLBCL); high grade B cell lymphoma; mantle cell lymphoma (MCL); relapsed and refractory lymphoma; CENTRAL-NERVOUS-SYSTEM; AXICABTAGENE CILOLEUCEL; COST-EFFECTIVENESS; BREXUCABTAGENE AUTOLEUCEL; PREDICTIVE FACTORS; OUTCOMES; MULTICENTER; INFLAMMATION; PERSISTENCE; IBRUTINIB;

D O I：

10.3389/fonc.2024.1394057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma, highlighting their efficacy and toxicity as well as discussing future directions.

引用

页数：13

共 50 条

[1] Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma
Hamilton, Mark P.
Miklos, David B.
[J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1053 - 1075
[2] Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas
Johnson, P. Connor
Abramson, Jeremy S.
[J]. LEUKEMIA & LYMPHOMA, 2020, 61 (11) : 2561 - 2567
[3] Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products
Hunter, Bradley D.
Rogalski, Michael
Jacobson, Caron A.
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1157 - 1164
[4] Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas
Anagha Deshpande
William Rule
Allison Rosenthal
[J]. Current Treatment Options in Oncology, 2022, 23 : 89 - 98
[5] Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas
Deshpande, Anagha
Rule, William
Rosenthal, Allison
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (01) : 89 - 98
[6] Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas
Shengnan Ding
Xia Mao
Yang Cao
Na Wang
Hao Xu
Jianfeng Zhou
[J]. Targeted Oncology, 2020, 15 : 365 - 375
[7] Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas
Ding, Shengnan
Mao, Xia
Cao, Yang
Wang, Na
Xu, Hao
Zhou, Jianfeng
[J]. TARGETED ONCOLOGY, 2020, 15 (03) : 365 - 375
[8] Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas
Dodero, Anna
Bramanti, Stefania
Di Trani, Martina
Pennisi, Martina
Ljevar, Silva
Chiappella, Annalisa
Massimo, Magagnoli
Guidetti, Anna
Corrado, Francesco
Nierychlewska, Paulina Maria
Di Rocco, Alice
Lorenzini, Daniele
Daoud, Rahal
De Philippis, Chiara
Santoro, Armando
Carlo-Stella, Carmelo
Corradini, Paolo
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (01) : 151 - 159
[9] Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di, Mengyang
Potnis, Kunal C.
Long, Jessica B.
Isufi, Iris
Foss, Francine
Seropian, Stuart
Gross, Cary P.
Huntington, Scott F.
[J]. JNCI CANCER SPECTRUM, 2024, 8 (04)
[10] Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
Zhou, Wenyujing
Chen, Weihong
Wan, Xiaochun
Luo, Changru
Du, Xin
Li, Xiaoqing
Chen, Qian
Gao, Ruiwen
Zhang, Xiaohan
Xie, Mei
Wang, Mingjun
[J]. FRONTIERS IN GENETICS, 2022, 12

← 1 2 3 4 5 →